Australia-based Proteomics International Laboratories has collaborated with drug company Dimerix to use its PromarkerD test for improving the treatment of chronic kidney disease (CKD).

PromarkerD is a predictive and diagnostic test designed to measure a protein biomarker panel in the blood to detect diabetic kidney disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Proteomics said that during clinical studies, the test has demonstrated the ability to predict rapid kidney function decline around four years in advance.

The firms will assess the performance of the PromarkerD test with Dimerix’s drug therapy candidate DMX-200 in early-phase clinical trials for chronic kidney disease, which usually goes undetected until very advanced stages.

DMX-200 is reported to have indicated promising efficacy profile in a separate Phase IIa trial performed in diabetic kidney disease patients.

“Having a test which can predict disease progression will undoubtedly be beneficial to both controlling disease and treating it with new drugs like DMX-200.”

PromarkerD is believed to possess the potential to act as a companion diagnostic test (CDx) in clinical trials to aid in evaluation and monitoring of a drug’s effectiveness.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Proteomics expects that the test will be used to assess the response of healthy volunteers in Dimerix’s ongoing Phase I pharmacokinetic (PK) study being conducted at Linear Clinical Research in Perth, Australia, as well as in its upcoming Phase II programme.

It is anticipated that early disease detection with PromarkerD will enable early intervention with drugs such as DMX-200 and allow delay or prevention of the disease onset.

Dimerix CEO Kathy Harrison said: “Having a test which can predict disease progression will undoubtedly be beneficial to both controlling disease and treating it with new drugs like DMX-200.”